Gadfin Ltd. and Israel Acquisitions Corp. Announce Entry into Definitive Business Combination Agreement, Bringing the Unmanned Aerial Delivery Company to Nasdaq

(NasdaqGM:ISRL),(NasdaqGM:ISRLW), TEL-AVIV, Israel, Jan. 27, 2025 (GLOBE NEWSWIRE) — Israel Acquisitions Corp. (NASDAQ: ISRL, ISRLU, ISRLW), (“ISRL”), a publicly-traded special purpose acquisition company, and Gadfin Ltd. (“Gadfin”), an Israeli technology company specializing in all-weather, long range, heavy-duty, drone delivery for essential cargo, today announced the entry into a definitive business combination agreement reflecting a total […]

Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis

(NasdaqGM:RNAC), FREDERICK, Md., Jan. 27, 2025 (GLOBE NEWSWIRE) — Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that it has received written agreement from the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process on the overall design of

Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces Restructuring

(NASDAQ:ALLK), – AK006 did not demonstrate therapeutic activity in CSU –– Allakos will discontinue further development of AK006, reduce workforce by 75% and explore strategic alternatives –– Management to host conference call and webcast today at 8:30 am E.T. – SAN CARLOS, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) — Allakos Inc. (Company) (Nasdaq: ALLK), today

SRQ Resources Grants Stock Options

(TSX-V – NEX Board:SRQ), MONTREAL, Jan. 27, 2025 (GLOBE NEWSWIRE) — SRQ Resources Inc. (TSXV: SRQ) (“SRQ” or the “Company) announced today a grant to the Directors and Officers an aggregate of 1,430,000 stock options (Incentive Options), each exercisable to acquire one Common Share at an exercise price of $0.13 on or before January 24,

First Participant Dosed in Tisento Therapeutics’ Global Phase 2b PRIZM Study Evaluating Zagociguat for the Treatment of MELAS

CAMBRIDGE, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) — Tisento Therapeutics today announced that the first patient has been dosed in its global Phase 2b PRIZM study. The study is investigating the impact of once-daily oral zagociguat treatment on fatigue, cognitive impairment, and other key aspects of the rare mitochondrial disease MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis,

Greenbacker secures nearly $1 billion financing to support acquisition and construction of largest solar project in New York State

Greenbacker, together with Hecate Energy, has completed the development of its largest clean energy project to date. After acquiring the project from Hecate, Greenbacker closed on construction financing in conjunction with commencing construction. Greenbacker partnered with six of the world's leading project finance banks and financial institutions to secure $869 million in construction-to-term, letter of

PyroGenesis Signs $2.5 Million Contract with Global Environmental Services Company

(TSX:PYR),(OTC US:PYRGF),(Other OTC:PYRGF),(Frankfurt:8PY), First payment of $400,000 received MONTREAL, Jan. 27, 2025 (GLOBE NEWSWIRE) — PyroGenesis Inc. (“PyroGenesis”) (http://pyrogenesis.com) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY), a high-tech company that designs, develops, manufactures and commercializes advanced plasma processes and sustainable solutions which are geared to reduce greenhouse gases (GHG) and address environmental pollutants, announces that its

Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference

(NASDAQ:TRML), NEW YORK, Jan. 27, 2025 (GLOBE NEWSWIRE) — Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer, is expected to participate in the following investor

JPMorgan Announces Cash Distributions for the JPMorgan ETFs

(TSX:JEPI),(TSX:JEPQ), TORONTO, Jan. 27, 2025 (GLOBE NEWSWIRE) — J. P. Morgan Asset Management (JPMAM)* today announced the final January 2025 cash distributions for the below listed JPMorgan ETFs. The JPMorgan ETFs trade on the Toronto Stock Exchange (TSX). Unitholders of record on February 3, 2025 will receive cash distributions payable on February 7, 2025. Details

Hopebridge celebrates 20 years of compassionate autism care

Indianapolis, Jan. 27, 2025 (GLOBE NEWSWIRE) — Hopebridge Autism Therapy Centers, one of the largest autism therapy providers in the nation, is celebrating 20 years of serving children and families affected by autism spectrum disorder (ASD) and developmental delays. As one of the few providers within the applied behavior analysis (ABA) space to reach this

Scroll to Top